> top > docs > PubMed:33166694 > annotations

PubMed:33166694 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T1 127-131 Body_part denotes BACK http://purl.org/sig/ont/fma/fma25056

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T1 78-86 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T2 165-173 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T3 255-263 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T4 334-342 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T5 376-384 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T6 387-396 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550
T7 446-454 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T8 508-516 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T9 734-742 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T10 1192-1200 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T11 1266-1274 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T12 1293-1301 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T13 1488-1496 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T14 1585-1593 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T15 1894-1902 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T16 2061-2069 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T17 2331-2339 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T18 2380-2383 Disease denotes PRS http://purl.obolibrary.org/obo/MONDO_0010667

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T1 88-89 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T2 98-99 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T3 423-426 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T4 632-637 http://purl.obolibrary.org/obo/CLO_0007225 denotes label
T5 878-881 http://purl.obolibrary.org/obo/CLO_0054061 denotes 132
T6 1362-1365 http://purl.obolibrary.org/obo/CLO_0054061 denotes 132
T7 1412-1414 http://purl.obolibrary.org/obo/CLO_0001313 denotes 36
T8 1854-1857 http://purl.obolibrary.org/obo/CLO_0051582 denotes has

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T1 113-116 Chemical denotes PEP http://purl.obolibrary.org/obo/CHEBI_18021|http://purl.obolibrary.org/obo/CHEBI_44897
T3 198-203 Chemical denotes drugs http://purl.obolibrary.org/obo/CHEBI_23888
T4 570-573 Chemical denotes PEP http://purl.obolibrary.org/obo/CHEBI_18021|http://purl.obolibrary.org/obo/CHEBI_44897
T6 632-637 Chemical denotes label http://purl.obolibrary.org/obo/CHEBI_35209
T7 871-874 Chemical denotes PEP http://purl.obolibrary.org/obo/CHEBI_18021|http://purl.obolibrary.org/obo/CHEBI_44897
T9 915-918 Chemical denotes PEP http://purl.obolibrary.org/obo/CHEBI_18021|http://purl.obolibrary.org/obo/CHEBI_44897
T11 919-924 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T12 1339-1342 Chemical denotes PEP http://purl.obolibrary.org/obo/CHEBI_18021|http://purl.obolibrary.org/obo/CHEBI_44897
T14 1343-1348 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T15 1403-1408 Chemical denotes group http://purl.obolibrary.org/obo/CHEBI_24433
T16 1841-1844 Chemical denotes PEP http://purl.obolibrary.org/obo/CHEBI_18021|http://purl.obolibrary.org/obo/CHEBI_44897
T18 1976-1979 Chemical denotes PEP http://purl.obolibrary.org/obo/CHEBI_18021|http://purl.obolibrary.org/obo/CHEBI_44897
T20 2305-2308 Chemical denotes PEP http://purl.obolibrary.org/obo/CHEBI_18021|http://purl.obolibrary.org/obo/CHEBI_44897
T22 2384-2386 Chemical denotes ID http://purl.obolibrary.org/obo/CHEBI_141439

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
4 31-49 Chemical denotes Hydroxychloroquine MESH:D006886
5 51-54 Chemical denotes HCQ MESH:D006886
6 78-86 Disease denotes COVID-19 MESH:C000657245
7 113-116 Gene denotes PEP Gene:5550
39 165-173 Disease denotes COVID-19 MESH:C000657245
40 255-263 Disease denotes COVID-19 MESH:C000657245
41 334-342 Disease denotes COVID-19 MESH:C000657245
42 343-351 Species denotes patients Tax:9606
43 376-396 Disease denotes SARS-CoV-2 infection MESH:C000657245
44 398-416 Chemical denotes Hydroxychloroquine MESH:D006886
45 418-421 Chemical denotes HCQ MESH:D006886
46 446-454 Disease denotes COVID-19 MESH:C000657245
47 508-518 Species denotes SARS-CoV-2 Tax:2697049
48 536-539 Chemical denotes HCQ MESH:D006886
49 570-573 Gene denotes PEP Gene:5550
50 734-742 Disease denotes COVID-19 MESH:C000657245
51 837-840 Chemical denotes HCQ MESH:D006886
52 871-874 Gene denotes PEP Gene:5550
53 915-918 Gene denotes PEP Gene:5550
54 941-944 Chemical denotes HCQ MESH:D006886
55 1192-1200 Disease denotes COVID-19 MESH:C000657245
56 1231-1243 Species denotes participants Tax:9606
57 1266-1274 Disease denotes COVID-19 MESH:C000657245
58 1293-1301 Disease denotes COVID-19 MESH:C000657245
59 1339-1342 Gene denotes PEP Gene:5550
60 1488-1496 Disease denotes COVID-19 MESH:C000657245
61 1585-1593 Disease denotes COVID-19 MESH:C000657245
62 1786-1798 Species denotes participants Tax:9606
63 1841-1844 Gene denotes PEP Gene:5550
64 1850-1853 Chemical denotes HCQ MESH:D006886
65 1894-1902 Disease denotes COVID-19 MESH:C000657245
66 1976-1979 Gene denotes PEP Gene:5550
67 2061-2069 Disease denotes COVID-19 MESH:C000657245
68 2305-2308 Gene denotes PEP Gene:5550
69 2331-2339 Disease denotes COVID-19 MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T1 0-108 Sentence denotes Post Exposure Prophylaxis with Hydroxychloroquine (HCQ) for the Prevention of COVID-19, a Myth or a Reality?
T2 109-126 Sentence denotes The PEP-CQ Study.
T3 127-139 Sentence denotes BACK GROUND:
T4 140-296 Sentence denotes Since the arrival of the COVID-19 pandemic many available drugs have been tried for the treatment or prevention of COVID-19 with limited success or failure.
T5 297-397 Sentence denotes The household direct contacts of the COVID-19 patients are at highest risk for SARS-CoV-2 infection.
T6 398-610 Sentence denotes Hydroxychloroquine (HCQ) has been tried against COVID-19 in the view of its in-vitro virucidal action against SARS-CoV-2, but the role of HCQ as post exposure prophylaxis (PEP) is still inconclusive and evolving.
T7 611-618 Sentence denotes METHOD:
T8 619-910 Sentence denotes In this open label control clinical trial asymptomatic individual who had direct contact with laboratory confirmed COVID-19 cases or had undertaken international travel in last 2 weeks were given the option for taking HCQ prophylaxis and assigned into PEP (N=132) and control groups (N=185).
T9 911-1006 Sentence denotes The PEP group received tablet HCQ 800 mg on day one followed by 400 mg once weekly for 3 weeks.
T10 1007-1201 Sentence denotes Both the groups received standard care of therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene and followed up for 4 weeks for new onset COVID-19.
T11 1202-1210 Sentence denotes RESULTS:
T12 1211-1275 Sentence denotes Total 50 out of 317 participants (15.8%) had new onset COVID-19.
T13 1276-1436 Sentence denotes The incidence of COVID-19 was significantly (p=0.033) lower in PEP group [N=14 out of 132, (10.6%)] as compared to the control group [N=36 out of 185, (19.4%)].
T14 1437-1514 Sentence denotes Total absolute risk reduction for the incidence of COVID-19 was -8.8% points.
T15 1515-1601 Sentence denotes The number needed to treat (NNT) to prevent occurrence of one case of COVID-19 was 12.
T16 1602-1677 Sentence denotes The overall relative risk was 0.59 (95% confidence interval, 0.33 to 1.05).
T17 1678-1828 Sentence denotes The compliance was good and most common ADR was epigastric discomfort with burning sensation, reported by 3 participants and no serious ADR was noted.
T18 1829-1926 Sentence denotes CONCLUSION: PEP with HCQ has the potential for the prevention of COVID-19 in at-risk individuals.
T19 1927-2133 Sentence denotes Till definitive therapy is available, continuing PEP with HCQ may be considered in suitable at-risk individuals for the prevention of COVID-19, as endorsed by many national/international health authorities.
T20 2134-2340 Sentence denotes The present study will encourage the researchers around the globe to reconsider further randomized clinical trials with larger sample size for better evaluation of HCQ as PEP for the prevention of COVID-19.
T21 2341-2399 Sentence denotes TRIAL REGISTRATION: clinicaltrials.gov PRS ID: CT04408456.